The question now is what impact that may have on Johnson & Johnson, which has been battling class-action litigation claiming that its talc-based products like Johnson’s Baby Powder have caused ...

Key Takeaways The Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively.